News

Technology News

AMAG Pharmaceuticals Launches Feraheme IV Treatment

Tuesday, July 14, 2009 5:02:00 AM PDT | VentureDeal Staff
Lexington, Massachusetts  --  Pharmaceutical company AMAG Pharmaceuticals (NASDAQ: AMAG) announced the US launch of a new iron replacement therapy for iron deficiency anemia in adult patients.

Called Feraheme, the therapy is delivered intravenously to patients with chronic kidney disease.

The product was approved for sale by the FDA on June 30, 2009 and will have a wholesale acquisition cost of $396.78 per 510 mg vial.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1